Veralipride (Standard)
Veralipride (Standard) is the analytical standard of Veralipride. This product is intended for research and analytical applications. Veralipride is a D2 receptor antagonist. It is an alternative antidopaminergic treatment for menopausal symptoms.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 98%
- No. CAS: 66644-81-3
- Fòrmula: C17H25N3O5S
- Peso molecular:383.46
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Pureza y Documentación
-
Help & FAQs
-
HY-101797
Veralipride -
HY-B0623A
Ropinirole hydrochlorideD3/D2 Receptor Agonist -
HY-B1019
SulpirideD2/D3 Receptor Antagonist -
HY-17382
Metoclopramide5-HT3/D2 Receptor Antagonist -
HY-B0410
PramipexoleDopamine Receptor Agonist -
HY-A0081
Fluphenazine dihydrochlorideDopamine Receptor Inhibitor -
HY-B0274
ChlorprothixeneNeuroprotective Agent -
HY-B1059
LevosulpirideDopamine Receptor Antagonist -
HY-B1019R
Sulpiride (Standard)D2/D3 Receptor Antagonist -
HY-B1196
Tiapride hydrochlorideD2/D3 Dopamine Receptor Antagonist -
HY-B0623AR
Ropinirole hydrochloride (Standard)D3/D2 Receptor Agonist -
HY-17382R
Metoclopramide (Standard)5-HT3/D2 Receptor Antagonist
Product Information
Information
Aplicación
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
No. CAS 66644-81-3
-
Peso molecular 383.46
-
Fòrmula C17H25N3O5S
-
SMILES
O=C(NCC1N(CC=C)CCC1)C2=CC(S(=O)(N)=O)=CC(OC)=C2OC
-
Synonyms
(±)-Veralipride (Standard); LIR166 (Standard)
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1]. Melis GB, et al. Effects of the dopamine antagonist veralipride on hot flushes and luteinizing hormone secretion in postmenopausal women. Obstet Gynecol. 1988 Nov;72(5):688-92. [Content Brief]
[2]. Carranza-Lira S, et al. Actual status of veralipride use. Clin Interv Aging. 2010 Sep 7;5:271-6. [Content Brief]
[3]. Valencia MH, e al. Safety of veralipride for the treatment of vasomotor symptoms of menopause. Menopause. 2014 May;21(5):484-92. [Content Brief]
[4]. Franchignoni FP, et al. Parkinson syndrome induced by veralipride. Minerva Ginecol. 1995 Jun;47(6):277-9. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Veralipride (Standard) Related Classifications
HY-101797R Related Classifications
Powered by Bioz